Adjunctive Antipsychotics for Major Depression
Adjunctive Antipsychotics for Major Depression
September 19, 2011 (Issue: 1373)
Augmentation with a second-generation (atypical) antipsychotic is a treatment option for patients with major
depressive disorder (MDD) whose symptoms persist following antidepressant monotherapy. Aripiprazole (Abilify), olanzapine in a fixed-dose...more
1. J Chen et al. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry 2011; 24:10.
2. RM Berman et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68:843.
3. RN Marcus et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 2:156.
4. MH Trivedi et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry 2008; 69:1928.
5. RM Berman et al. Long-term safety and tolerability of openlabel aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat 2011; 7:303.
6. Olanzapine/fluoxetine (Symbyax) for bipolar depression. Med Lett Drugs Ther 2004; 46:23.
7. MH Trivedi et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009; 70:387.
8. M Bauer et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010; 127:19.
9. RA Mahmoud et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007; 147:593.
10. GI Keitner et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009; 43:205.
11. AJ Rush et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Adjunctive Antipsychotics for Major Depression
Article code: 1373b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
